3Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153. 被引量：1
4Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545. 被引量：1
5Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301. 被引量：1
6Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754. 被引量：1
7Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408. 被引量：1
8Ramirez J A, Mgayen T.Treating community-acqured pneumonia with once- daily gatifloxacin VS twice-daily clarithromycin. J Respir Dis, 1999, 20:s60-69. 被引量：1
9Forrest A, Nix DE,Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 1993, 37:1073-1081 被引量：1
10Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis , 1998, 27:33-39. 被引量：1
4Dartois N,Cooper CA,Castaing N,et al.Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia:an analysis of risk factors[J].Open Respir Med J,2013,7(13):20-21 被引量：1
5Ramirez JA,Cooper AC,Wiemken T,et al.Switch therapy in hospitalized patients with community-acquired pneumonia:tigecycline vs.levofloxacin[J].BMC Infect Dis,2012,19(12):159-160 被引量：1
6Biedenbach DJ,Farrell DJ,Flamm RK,et al.Activity of JNJ-Q2,a new fluoroquinolone,tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia[J].Int J Antimicrob Agents,2012,39(4):321-325 被引量：1
7Plusa T.Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections[J].Pol Merkur Lekarski,2011,30(176):91-96 被引量：1
8Oldach D,Clark K,Schranz J,et al.Randomized,double-blind,multicenter phase 2 study comparing the efficacy and safety of oral solithromycin(CEM-101)to those of oral Levofloxacin in the treatment of patients with community-acquired bacterial pneumonia[J].Antimicrob Agents Chemother,2013,57(6):2526-2534 被引量：1
9Vouloumanou EK,Plessa E,Karageorgopoulos DE,et al.Serum procalcitonin as a diagnostic marker for neonatal sepsis:a systematic review andmeta-analysis[J].Intensive Care Med,2011,3(5):201-204. 被引量：1
10Redl H,Schlag G,Tgel E,et al.Procalcitonin release patterns in a baboon model of trauma and sepsis:relationship to cytokinesand neopterin[J].Crit Care Med,2000,28(11):3659-3663. 被引量：1
